Landmark moment for science as the FDA approves a gene therapy for the first time

(Boston Children’s Hospital) Dana-Farber/Boston Children’s recently participated in a similar clinical trial of CAR T-cells that evaluated the efficacy of CAR T-cell therapy in treating relapsed or treatment-resistant B-cell ALL.’The lessons learned from the clinical trials of CAR T-cell operations will assist us in being able to provide to the larger population,’ says Colleen Dansereau, MSN, RN and CPN, who is director of clinical research nursing and gene therapy program manager at Dana-Farber/Boston Children’s.